Optimizing Radiotherapy With Immunotherapy in Lung Cancer Treatment
This video examines how the use of radiation therapy in patients on immunotherapy can trigger immunogenic cell death, and reviews some of the challenges related to unwanted immune responses from radiotherapy.
Several reports have described how the use of radiation therapy in patients on immunotherapy can trigger immunogenic cell death.
In this video, Ramesh Rengan, MD, PhD, of the University of Washington in Seattle, highlights research aiming to optimize this combination of radiation therapy and immunotherapy, and discusses unwanted immune responses from radiotherapy and the challenge of utilizing this combination in patients with brain metastases.
Rengan gave a presentation on this topic at the 2017 Multidisciplinary Thoracic Cancers Symposium.
Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer
September 18th 2018ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.
Adjuvant Pembrolizumab Earns European Approval for High-Risk NSCLC
October 26th 2023Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.
Pembrolizumab/Chemo Appears to Improve Survival in Advanced Mesothelioma
March 13th 2023The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
